PFKFB3 and malignant pleural mesothelioma: As a small molecular antagonist of PFKFB3, PFK158 can mimic genetic inhibition of PFKFB3 (thus inhibiting glycolytic activity), arrest tumor cells in G0/G1 phase, and promote cell death as well as enhance chemotherapy in malignant pleural mesothelioma (22).